PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCI
Under the Panerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO		Complete if Known			
Substitute for form 1770/110				Application Number	10/575,671
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	July 25, 2008
				First Named Inventor	Bradley T. Messmer
(Use as many sheets as necessary)			ococcaru)	Art Unit	1642
			ecessary)	Examiner Name	Sean E. Aeder
Sheet	1	of	2	Attorney Docket Number	50425/245

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Include name of the item (book,		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	A copy of the International Search Report for PCT Application No. PCT/US2004/033176. 6/16/05	
	2	A copy of the Written Opinion of the International Searching Authority for PCT Application No. PCT/US2004/033176. 6/16/05	
	3	A copy of the International Preliminary Report on Patentability for PCT Application No. PCT/US2004/033176. 6/16/05	
	4	A copy of the Office Action for European Application No. 04 794 503.5, dated February 2, 2010.	
	5	A copy of the Office Action for European Application No. 04 794 503.5, dated April 9, 2008.	
	6	VALETTO et al. "Chronic Lymphoid Leukemia." Bio. and Clin. Invest. III, Abstract #1784, p. 431a. 1998	
	7	FAIS et al. "Chronic Lymphocytic Leukemia B Cells Express Restricted Sets of Mutated and Unmutated Antigen Receptors." J. Clin. Invest. (1998), vol. 102, pp. 1515-25.	
	8	DAMLE et al. "Ig V Gene Mutation Status and CD38 Expression as Novel Prognostic Indicators in Chronic Lymphocytic Leukemia." Blood, Sept. 15, vol. 94, pp. 1840-47.	
	9	CHIORAZZI et al. "Immunoglobulin Variable Region Gene Characteristics and Surface Membrane Phenotype Define B-CLL Subgroups with Distinct Clinical Courses."	
		Chronic Lymphoid Leukemia, Marcel Dekker, New York, NY, US (2001) pp. 81-109.	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known		
Cubatitude for form 1.116/1.110	Application Number	10/575,671	
INFORMATION DISCLOSURE	Filing Date	July 25, 2008	
STATEMENT BY APPLICANT	First Named Inventor	Bradley T. Messmer	
(Use as many sheets as necessary)	Art Unit	1642	
(Use as many sneets as necessary)	Examiner Name	Sean E. Aeder	
Sheet 1 of 2	Attorney Docket Number	50425/245	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	10	GHIOTTO et al. "Remarkably Similar Antigen Receptors Among a Subset of Patients with Chronic Lymphocytic Leukemia." J. of Clin. Invest. Vol. 113:7, pp. 1008-1011.	
	11	CARTER "Improving the Efficacy of Antibody-Based Cancer Therapies." Nature Reviews (2001) vol. 1, pp. 119-129.	
	12	CHIORAZZI et al. "B Cell Chronic Lymphocytic Leukemia: Lessons Learned from Studies of the B Cell Antigen Receptor." Annu. Rev. Immunol. 2005, 21:841-894.	
With the second			<u> </u>

parameter section and the sect			
Examiner		Date	
LL XCGITTITIO!	108		
Signature	Sean Aeder/ (01/14/2011)	Considered	
Digitature	1 7000117100011 (01171112011)		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.